Proactive Investors - Run By Investors For Investors

AusCann Group’s MacLeman buys shares on-market

This purchase follows recent buying from the company’s board’s chairman.
man with briefcase running up ascending share price arrow
MacLeman is serving as interim CEO and will be replaced by Ido Kanyon in May 2019

AusCann Group Holdings Ltd’s (ASX:AC8) interim CEO and director Paul MacLeman has purchased 30,268 shares priced at 33 cents each via on-market trades.

MacLeman is an experienced pharmaceutical executive and was appointed to the company’s board in September 2018.

This is MacLeman’s first purchase of company shares.

READ: AusCann Group chairman buys $58,238 worth of shares on-market

In late February 2019, AusCann appointed global pharmaceutical business executive Ido Kanyon as its CEO commencing 22 May 2019.

Kanyon brings more than 15 years’ senior executive experience in the pharmaceutical industry most recently at multi-billion dollar Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

A WeedMD greenhouse
January 21 2019
WeedMD produces cannabis and cannabis oil for both the medical and adult-use markets
cannabis leaf next to bottle
April 29 2019
The cannabis holding company has four unique, synergistic business under its umbrella
medicinal cannabis concept
January 30 2019
Zelda has released its December quarterly report confirming multiple trials are on track.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use